UZEDY Sales Surge Fuels Medincell Royalty Stream, Eyes European Expansion
Event summary
- UZEDY® net sales reached $191 million in 2025, a 63% increase from $117 million in 2024.
- Teva projects UZEDY® net sales of $250 - $280 million in 2026.
- Medincell receives mid-to-high single-digit royalties on UZEDY® sales and is eligible for up to $105 million in milestone payments.
- Teva plans to submit Olanzapine LAI for EU approval in Q2 2026.
- Teva submitted an NDA for Olanzapine LAI to the FDA in December 2025.
The big picture
Medincell’s reliance on Teva for UZEDY® sales highlights the inherent risks of a licensing model, but the substantial revenue growth demonstrates the potential of its BEPO® technology. The planned EU expansion for Olanzapine LAI represents a significant opportunity to broaden Medincell’s revenue base, but success hinges on navigating European regulatory hurdles and competitive pressures within the antipsychotic market.
What we're watching
- Regulatory Headwinds
- The EMA review process, including the CHMP opinion, will be critical; delays could significantly impact Medincell’s milestone payment schedule and overall revenue projections.
- Execution Risk
- Teva’s ability to achieve its 2026 sales forecast for UZEDY will directly influence Medincell’s royalty income and milestone eligibility, requiring close monitoring of market uptake and competitive dynamics.
- Market Dynamics
- How the introduction of Olanzapine LAI impacts the broader schizophrenia treatment landscape and potentially cannibalizes existing olanzapine sales will shape Medincell’s long-term revenue streams.
Related topics